- Appointment further strengthens commercial skincare business
where Company was first to launch products into Colombia market in 2018
- Skincare unit targets $10 Billion
Latin America skincare market
- Dr. Bendek a recognized pioneer in CBD cosmeceutical product
innovation
- Appointment expands expertise in general dermatology, cutaneous
surgery, anti-aging dermatology and predictive genetics with
appointment of Dr. Bendek
TORONTO, March, 13, 2019 /CNW/
- Khiron Life Sciences Corp. ("Khiron" or the "Company")
(TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated
cannabis leader with core operations in Latin America, announced today the appointment
of Dr. Edwin Bendek MD, MA, MPH as
Medical Director, Skincare. This appointment expands the Company's
scientific expertise and resources for future product and brand
development, global strategic alliances and research and education
initiatives across Latin
America.
Andres Galofre, Khiron Co-founder
and VP Business Development, stated, " The appointment of Dr.
Bendek is an important addition to our skincare unit as we ramp up
retail distribution, and further advance new product research and
development. Dr. Bendek's proven skincare and cosmetology
experience, together with his exceptional industry network will be
invaluable as we execute our research-based, product development
strategy."
Dr. Bendek, brings 20 years of global experience in general
dermatology, cutaneous surgery, anti-aging dermatology and
predictive genetics. A graduate of Medical Dermatology from
Universidad Javeriana, Colombia,
specialist in anti-aging from the WOSIAM in Paris, Master in Public Health from the
Universidad de Granada, Master in
Bioethics, Health and Law from the Université de Rennes and
Specialist in clinical trials from Harvard
University, Dr. Bendek is a regular speaker at national and
international events, and is considered a pioneer in CBD
cosmeceutical product development.
Khiron's skincare unit, which operates within the Company's
previously announced Wellness unit, developed
Kuida®, It's first consumer brand that brings the
benefits of cannabidiol (CBD) to a comprehensive portfolio of skin
and body care products for women. Kuida® was launched in
October, 2018 and is available to consumers in-store, online and
through strategic ecommerce partnerships across Colombia.
Dr. Bendek, stated, "I am pleased to join the Khiron team at a
very important time for our industry. CBD comseceutical products
are rapidly gaining acceptance among retailers, health
professionals and consumers who recognize the role these products
can play in a beauty and health care regime. I look forward to
working with my colleagues as we develop product innovations for an
increasingly global market."
About Khiron
Khiron Life Sciences Corp. is positioned to be the dominant
integrated cannabis company in Latin
America. Khiron has core operations in Colombia and is fully licensed in the country
for the cultivation, production, domestic distribution, and
international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
one of the first Colombian based medical cannabis companies to
trade on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at https://investors.khiron.ca/
Cautionary Notes
Market and Industry Data
This press release contains market and industry data and forecasts
that were obtained from third-party sources, industry publications
and publicly available information. Third-party sources generally
state that the information contained therein has been obtained from
sources believed to be reliable, but there can be no assurance as
to the accuracy or completeness of included information. Although
management believes it to be reliable, the Company has not
independently verified any of the data from third-party sources
referred to in this press release, or analyzed or verified the
underlying studies or surveys relied upon or referred to by such
sources, or ascertained the underlying economic assumptions relied
upon by such sources.
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable Canadian securities legislation. All information
contained herein that is not historical in nature may constitute
forward-looking information. Forward-looking statements may be
identified by statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Forward-looking statements herein include, but are not limited to,
statements regarding the final acceptance of the TSXV and the
commencement of sales in Mexico.
Readers are cautioned to not place undue reliance on
forward-looking information. Actual results and developments may
differ materially from those contemplated by these statements.
Khiron undertakes no obligation to comment analyses, expectations
or statements made by third-parties in respect of Khiron, its
securities, or financial or operating results (as applicable).
Although Khiron believes that the expectations reflected in
forward-looking statements in this press release are reasonable,
such forward-looking statement has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Khiron's control, including the risk
factors discussed in Khiron's Annual Information Form which is
available on Khiron's SEDAR profile at www.sedar.com. The
forward-looking information contained in this press release is
expressly qualified by this cautionary statement and are made as of
the date hereof. Khiron disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking information, whether as a result of
new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.